Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808808376> ?p ?o ?g. }
- W2808808376 endingPage "134.e5" @default.
- W2808808376 startingPage "126" @default.
- W2808808376 abstract "BackgroundChronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation.ObjectiveWe sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes.MethodsPatients (n = 323) 18 years and older with moderate-to-severe congestion and NPs were randomized to twice-daily EDS-FLU (93, 186, or 372 μg) or exhalation delivery system (EDS)–placebo for 24 weeks (16 double-blind plus 8 open-label when all received 372 μg). Coprimary end points were change in nasal congestion/obstruction at 4 weeks and summed bilateral polyp grade at 16 weeks. Secondary end points included symptoms, polyp elimination, and functioning.ResultsEDS-FLU was superior on both coprimary end points (P < .001 vs EDS-placebo, all doses). Mean polyp grade improved continuously through week 24 (P < .009, all comparisons), with polyps eliminated on at least 1 side in approximately 25% of patients at week 24 versus 8.7% with EDS-placebo (P ≤ .014, all comparisons). Sino-Nasal Outcomes Test scores also improved significantly versus those in patients receiving EDS-placebo (−21.1 to −21.4 vs −11.7 at week 16, P < .05 all doses). At the end of the double-blind period, EDS-FLU (all doses) significantly improved all 4 defining disease symptoms. In most patients (68%), those receiving EDS-FLU reported “much” or “very much” improvement. The number of patients eligible for surgery decreased by 62%-67%. The safety profile was similar to that reported in prior trials evaluating conventional corticosteroid nasal sprays in comparable populations.ConclusionEDS-FLU produces clinically and statistically significant improvement in all 4 diagnostically defining disease symptoms, polyp grade, and quality of life in patients with chronic rhinosinusitis with NPs. Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation. We sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes. Patients (n = 323) 18 years and older with moderate-to-severe congestion and NPs were randomized to twice-daily EDS-FLU (93, 186, or 372 μg) or exhalation delivery system (EDS)–placebo for 24 weeks (16 double-blind plus 8 open-label when all received 372 μg). Coprimary end points were change in nasal congestion/obstruction at 4 weeks and summed bilateral polyp grade at 16 weeks. Secondary end points included symptoms, polyp elimination, and functioning. EDS-FLU was superior on both coprimary end points (P < .001 vs EDS-placebo, all doses). Mean polyp grade improved continuously through week 24 (P < .009, all comparisons), with polyps eliminated on at least 1 side in approximately 25% of patients at week 24 versus 8.7% with EDS-placebo (P ≤ .014, all comparisons). Sino-Nasal Outcomes Test scores also improved significantly versus those in patients receiving EDS-placebo (−21.1 to −21.4 vs −11.7 at week 16, P < .05 all doses). At the end of the double-blind period, EDS-FLU (all doses) significantly improved all 4 defining disease symptoms. In most patients (68%), those receiving EDS-FLU reported “much” or “very much” improvement. The number of patients eligible for surgery decreased by 62%-67%. The safety profile was similar to that reported in prior trials evaluating conventional corticosteroid nasal sprays in comparable populations. EDS-FLU produces clinically and statistically significant improvement in all 4 diagnostically defining disease symptoms, polyp grade, and quality of life in patients with chronic rhinosinusitis with NPs." @default.
- W2808808376 created "2018-06-29" @default.
- W2808808376 creator A5011297503 @default.
- W2808808376 creator A5033012203 @default.
- W2808808376 creator A5039370667 @default.
- W2808808376 creator A5063293385 @default.
- W2808808376 creator A5065018970 @default.
- W2808808376 creator A5077352083 @default.
- W2808808376 date "2019-01-01" @default.
- W2808808376 modified "2023-10-11" @default.
- W2808808376 title "NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis" @default.
- W2808808376 cites W1946229283 @default.
- W2808808376 cites W1964050294 @default.
- W2808808376 cites W1968876836 @default.
- W2808808376 cites W1969313589 @default.
- W2808808376 cites W1990973234 @default.
- W2808808376 cites W1994848292 @default.
- W2808808376 cites W2000122897 @default.
- W2808808376 cites W2005362309 @default.
- W2808808376 cites W2009817795 @default.
- W2808808376 cites W2013336553 @default.
- W2808808376 cites W2020442272 @default.
- W2808808376 cites W2030674948 @default.
- W2808808376 cites W2032090121 @default.
- W2808808376 cites W2060167460 @default.
- W2808808376 cites W2065302886 @default.
- W2808808376 cites W2079731890 @default.
- W2808808376 cites W2080802372 @default.
- W2808808376 cites W2086214501 @default.
- W2808808376 cites W2090113525 @default.
- W2808808376 cites W2102013589 @default.
- W2808808376 cites W2104332007 @default.
- W2808808376 cites W2105880697 @default.
- W2808808376 cites W2109459905 @default.
- W2808808376 cites W2112843022 @default.
- W2808808376 cites W2114982455 @default.
- W2808808376 cites W2121440215 @default.
- W2808808376 cites W2128552597 @default.
- W2808808376 cites W2136539352 @default.
- W2808808376 cites W2143274250 @default.
- W2808808376 cites W2160716766 @default.
- W2808808376 cites W2165726810 @default.
- W2808808376 cites W2181392246 @default.
- W2808808376 cites W2266684950 @default.
- W2808808376 cites W2294068857 @default.
- W2808808376 cites W2336322188 @default.
- W2808808376 cites W2515977513 @default.
- W2808808376 cites W2552012052 @default.
- W2808808376 cites W2554368353 @default.
- W2808808376 cites W2587700905 @default.
- W2808808376 cites W2606085194 @default.
- W2808808376 cites W2734843221 @default.
- W2808808376 cites W2806994836 @default.
- W2808808376 cites W3183099619 @default.
- W2808808376 cites W4292806894 @default.
- W2808808376 cites W841511375 @default.
- W2808808376 doi "https://doi.org/10.1016/j.jaci.2018.06.010" @default.
- W2808808376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29928924" @default.
- W2808808376 hasPublicationYear "2019" @default.
- W2808808376 type Work @default.
- W2808808376 sameAs 2808808376 @default.
- W2808808376 citedByCount "65" @default.
- W2808808376 countsByYear W28088083762018 @default.
- W2808808376 countsByYear W28088083762019 @default.
- W2808808376 countsByYear W28088083762020 @default.
- W2808808376 countsByYear W28088083762021 @default.
- W2808808376 countsByYear W28088083762022 @default.
- W2808808376 countsByYear W28088083762023 @default.
- W2808808376 crossrefType "journal-article" @default.
- W2808808376 hasAuthorship W2808808376A5011297503 @default.
- W2808808376 hasAuthorship W2808808376A5033012203 @default.
- W2808808376 hasAuthorship W2808808376A5039370667 @default.
- W2808808376 hasAuthorship W2808808376A5063293385 @default.
- W2808808376 hasAuthorship W2808808376A5065018970 @default.
- W2808808376 hasAuthorship W2808808376A5077352083 @default.
- W2808808376 hasBestOaLocation W28088083761 @default.
- W2808808376 hasConcept C126322002 @default.
- W2808808376 hasConcept C141071460 @default.
- W2808808376 hasConcept C142724271 @default.
- W2808808376 hasConcept C168563851 @default.
- W2808808376 hasConcept C204787440 @default.
- W2808808376 hasConcept C27081682 @default.
- W2808808376 hasConcept C2776804153 @default.
- W2808808376 hasConcept C2777844070 @default.
- W2808808376 hasConcept C2778311950 @default.
- W2808808376 hasConcept C2779028295 @default.
- W2808808376 hasConcept C2781212218 @default.
- W2808808376 hasConcept C2781390199 @default.
- W2808808376 hasConcept C2991744798 @default.
- W2808808376 hasConcept C42219234 @default.
- W2808808376 hasConcept C43396882 @default.
- W2808808376 hasConcept C71924100 @default.
- W2808808376 hasConcept C90924648 @default.
- W2808808376 hasConceptScore W2808808376C126322002 @default.
- W2808808376 hasConceptScore W2808808376C141071460 @default.
- W2808808376 hasConceptScore W2808808376C142724271 @default.
- W2808808376 hasConceptScore W2808808376C168563851 @default.
- W2808808376 hasConceptScore W2808808376C204787440 @default.